IP Library Granted Patent US 10,583,145
Granted Patent B2
US 10,583,145 · App. 16/221,094 · Granted Mar 10, 2020

Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

Inventors: Thomas J. Slaga (San Antonio, TX); Jacob Junco (San Antonio, TX); Huiyun Liang (San Antonio, TX); Sara Reyna (San Antonio, TX)
Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
A61K31/56A61K9/0053A61K31/05A61K31/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,583,145
App. No.
16/221,094
Granted
Mar 10, 2020
Kind
B2
Abstract

Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.

Claims (20)

1. A composition comprising ursolic acid and resveratrol, wherein the ratio of ursolic acid to resveratrol is the range of 3:1 to 1:3.

2. The composition of claim 1 , wherein the composition is a single dose composition.

3. The composition of claim 2 , wherein the single dose composition comprises 50 to 600 mg of ursolic acid.

4. The composition of claim 2 , wherein the single dose composition comprises 200 mg of ursolic acid.

5. The composition of claim 2 , wherein the single dose composition comprises 50 to 600 mg resveratrol.

6. The composition of claim 2 , wherein the single dose composition comprises 600 mg of resveratrol.

7. The composition of claim 2 , wherein the single dose composition comprises 200 mg of ursolic acid and 600 mg of resveratrol.

8. The composition of claim 2 , wherein the single dose composition comprises 100 mg of ursolic acid and 200 mg of resveratrol.

9. The composition of claim 1 , further comprising an anti-diabetic drug.

10. The composition of claim 9 , wherein the anti-diabetic drug is Rosiglitazone or Metformin.

11. The composition of claim 1 , further comprising one or more of a preserving, an emulsifying, or a dispersing agent.

12. The composition of claim 1 , further comprising one or more of a filler or extender, a binder, a humectant, a disintegrating agent, solution retarder, absorption accelerator, wetting agent, an adsorbent, lubricant, or buffering agent.

13. The composition of claim 12 , wherein the filler is starch, lactose, sucrose, mannitol, or silicic acid.

14. The composition of claim 12 , wherein the binder is carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, or acacia.

15. The composition of claim 12 , wherein the humectant is glycerol.

16. The composition of claim 12 , wherein the disintegrating agent is agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, complex silicates, or sodium carbonate.

17. The composition of claim 12 , wherein the solution retarder is paraffin.

18. The composition of claim 12 , wherein the wetting agent is cetyl alcohol or glycerol monostearate.

19. The composition of claim 12 , wherein the lubricant is talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof.

20. The composition of claim 1 , wherein the composition is a tablet, a capsule, a concentrate, a powder, a drink, a baked good, chocolate, caramel, and/or snack.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2019
From: SLAGA, THOMAS J; JUNCO, JACOB; LIANG, HUIYUN
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 048040/0861 →
Continuity (3)
Continuation 15308427
Provisional Application 61988859 · May 5, 2014
Related Publication 20190192537A1 · Jun 27, 2019